Delayed reactions to Acetaminophen

Abstract

Catal a Oncol ogic (2) Unitat Diagn ostic Al.l ergia Medicamentosa. UDAM. Barcelona. Spain (3) Brigham and Women's Hospital. Boston. USA RATIONALE: The Institut Catal a d'Oncologia, (ICO), publishes 4 per thousand of adverse reactions to chemotherapy, mediated or not by allergic mechanisms, and, in most cases, leaving the first therapeutic lines, for second one, safer, but less effective and undoubtedly higher direct costs. Our aim, to reverse that process, to get the opportunity to keep those patients with the best of possible medications. METHODS: 2 Part-time allergists, 1 nurse specialized in drug allergy, 1 Pharmaceutical, under the coordination of 1 Head of Unit First visit, skin tests, risk stratification and desensitization decision, place and number of steps The desensitization protocols used are from Brigham and Women's Hospital of Boston RESULTS: 285 patients, with different types and stages of cancer; 801 cycles of desensitization, mainly to Platins and taxanes; 98% of successes (reaching final dose prescribed by oncologist) 70% were 12-step cycles and 25% of 16; All in Day Hospital CONCLUSIONS: A Chemotherapy Drug Desensitization Unit, managed by allergists, increases the population's survival expectations with cancer, being able to maintain the first therapeutic line, recommended by the international guidelines, and that of another Form, they are confronted with second choices, safer perhaps, but clearly less effective